Clinical trial · no report yet · Phase 3
CheckMate 914
A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney
- NCT03138512 ↗
- Completed
- Bristol-Myers Squibb
- 81 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 33 | |
| Podcasts | 29 | |
| YouTube | 19 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Carcinoma, Renal Cell
- Interventions
- nivolumab; ipilimumab; nivolumab placebo; ipilimumab placebo
- Arms
- Part A, Arm A: nivolumab + ipilimumab · Experimental
- Part A, Arm B: nivolumab placebo + ipilimumab placebo · Placebo comparator
- Part B, Arm A: nivolumab + ipilimumab · Experimental
- Part B, Arm B: nivolumab placebo + ipilimumab placebo · Placebo comparator
- Part B, Arm C: nivolumab + ipilimumab placebo · Experimental
- Enrollment
- 1,641
- Primary outcomes
- Disease-Free Survival (DFS) by BICR - Treatment Part A and B
- Sponsor
- Bristol-Myers Squibb
- Start
- Jul 7, 2017
- Primary completion
- Sep 28, 2023
- Results posted
- Yes
- Registry record
- NCT03138512 · updated Dec 18, 2024
Publications
linked from the registry- Motzer RJ, Bex A, Russo P, Tomita Y, Cutuli HJ, Rojas C, Gross-Goupil M, Schinzari G, Melichar B, Barthelemy P, Ruiz Garcia A, Sosman J, Grimm MO, Goh JC, Suarez C, Kollmannsberger CK, Nair SG, Shuch BM, Huang J, Simsek B, Spiridigliozzi J, Lee CW, van Kooten Losio M, Grunwald V. Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial. J Clin Oncol. 2025 Jan 10;43(2):189-200. doi: 10.1200/JCO.24.00773. Epub 2024 Sep 20. PubMed 39303200
- Motzer RJ, Russo P, Grunwald V, Tomita Y, Zurawski B, Parikh O, Buti S, Barthelemy P, Goh JC, Ye D, Lingua A, Lattouf JB, Albiges L, George S, Shuch B, Sosman J, Staehler M, Vazquez Estevez S, Simsek B, Spiridigliozzi J, Chudnovsky A, Bex A. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet. 2023 Mar 11;401(10379):821-832. doi: 10.1016/S0140-6736(22)02574-0. Epub 2023 Feb 9. PubMed 36774933
- Marconi L, Sun M, Beisland C, Klatte T, Ljungberg B, Stewart GD, Dabestani S, Choueiri TK, Bex A. Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. Clin Genitourin Cancer. 2021 Apr;19(2):e92-e99. doi: 10.1016/j.clgc.2020.12.005. Epub 2021 Jan 7. PubMed 33526329